The goal of this clinical research study is to learn if giving donor lymphocyte cells and SGI-110 will help control acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) in patients who have had an allogeneic stem cell transplant (using someone else's stem cells) and have relapsed.